Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
O Yamaguchi, K Kaira, A Mouri, A Shiono… - Cancer chemotherapy …, 2019 - Springer
Background Re-challenge of erlotinib after gefitinib failure is reported to yield some benefit
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
JA Engle, JM Kolesar - American Journal of Health-System …, 2014 - academic.oup.com
Purpose The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects,
dosage and administration, and role in therapy of afatinib in the management of non-small …
dosage and administration, and role in therapy of afatinib in the management of non-small …
[HTML][HTML] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
L Kang, J Mai, W Liang, Q Zou, C Huang, Y Lin… - Frontiers in …, 2023 - frontiersin.org
Background: Afatinib is a potent, irreversible second-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non …
receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non …
[HTML][HTML] Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
A Passaro, A Pochesci, G Spitaleri… - Journal of Thoracic …, 2016 - ncbi.nlm.nih.gov
The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring …
(TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring …
[HTML][HTML] Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease …
AJ van der Wekken, JL Kuiper, A Saber, MM Terpstra… - PloS one, 2017 - journals.plos.org
Purpose To determine survival in afatinib-treated patients after treatment with first-
generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in …
generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in …
[HTML][HTML] A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study …
Y Minegishi, O Yamaguchi, S Sugawara, S Kuyama… - BMC cancer, 2021 - Springer
Background Lung cancer is most common among older individuals. However, polypharmacy
and comorbidities, which are also more common in older individuals, can limit treatment …
and comorbidities, which are also more common in older individuals, can limit treatment …
[HTML][HTML] Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with non-small cell lung cancer carrying uncommon …
HS Li, SZ Wang, HY Xu, X Yan, JY Zhang, SY Lei, T Li… - Cancers, 2022 - mdpi.com
Simple Summary Afatinib has been approved for patients with lung cancer carrying
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
[HTML][HTML] Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor …
Results We analyzed 422 patients with EGFR-mutated advanced lung adenocarcinoma
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases
JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …